PT3416964T - Derivados de 6-oxo-n-(1-(benzil)-1h-pirazol-4-il)-6,7,8,9- tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazina-2- carboxamida como inibidores de s6 quinase ribossómica p90 (rsk) para tratamento do cancro - Google Patents

Derivados de 6-oxo-n-(1-(benzil)-1h-pirazol-4-il)-6,7,8,9- tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazina-2- carboxamida como inibidores de s6 quinase ribossómica p90 (rsk) para tratamento do cancro

Info

Publication number
PT3416964T
PT3416964T PT177527421T PT17752742T PT3416964T PT 3416964 T PT3416964 T PT 3416964T PT 177527421 T PT177527421 T PT 177527421T PT 17752742 T PT17752742 T PT 17752742T PT 3416964 T PT3416964 T PT 3416964T
Authority
PT
Portugal
Prior art keywords
derivatives useful
carboxamide derivatives
rsk inhibitors
rsk
inhibitors
Prior art date
Application number
PT177527421T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Phoenix Molecular Designs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phoenix Molecular Designs filed Critical Phoenix Molecular Designs
Publication of PT3416964T publication Critical patent/PT3416964T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PT177527421T 2016-02-19 2017-02-17 Derivados de 6-oxo-n-(1-(benzil)-1h-pirazol-4-il)-6,7,8,9- tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazina-2- carboxamida como inibidores de s6 quinase ribossómica p90 (rsk) para tratamento do cancro PT3416964T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662297522P 2016-02-19 2016-02-19

Publications (1)

Publication Number Publication Date
PT3416964T true PT3416964T (pt) 2021-03-09

Family

ID=59625645

Family Applications (1)

Application Number Title Priority Date Filing Date
PT177527421T PT3416964T (pt) 2016-02-19 2017-02-17 Derivados de 6-oxo-n-(1-(benzil)-1h-pirazol-4-il)-6,7,8,9- tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazina-2- carboxamida como inibidores de s6 quinase ribossómica p90 (rsk) para tratamento do cancro

Country Status (15)

Country Link
US (4) US9771366B2 (enExample)
EP (2) EP3848373A1 (enExample)
JP (2) JP6912486B2 (enExample)
KR (1) KR102746242B1 (enExample)
CN (2) CN109071542B (enExample)
AU (1) AU2017220738B2 (enExample)
CA (1) CA3014395A1 (enExample)
CO (1) CO2018008846A2 (enExample)
DK (1) DK3416964T3 (enExample)
ES (1) ES2858753T3 (enExample)
IL (1) IL261170B (enExample)
MX (1) MX376974B (enExample)
PL (1) PL3416964T3 (enExample)
PT (1) PT3416964T (enExample)
WO (1) WO2017141116A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202319D0 (en) 2012-02-10 2012-03-28 Orbsen Therapeutics Ltd Stromal stem cells
WO2016154019A1 (en) 2015-03-20 2016-09-29 Orbsen Therapeutics Limited Modulators of syndecan-2 and uses thereof
HRP20210543T1 (hr) 2015-07-07 2021-05-14 H. Lundbeck A/S Inhibitori pde9 s imidazo triazinonskom okosnicom i imidazo pirazinonskom okosnicom za liječenje perifernih bolesti
US11918687B2 (en) 2016-01-15 2024-03-05 Orbsen Therapeutics Limited SDC-2 exosome compositions and methods of isolation and use
ES2858753T3 (es) 2016-02-19 2021-09-30 Phoenix Molecular Designs Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer
WO2019012334A2 (en) 2017-07-14 2019-01-17 Orbsen Therapeutics Limited METHODS OF ISOLATION AND USE OF CD39 STROMAL STEM CELLS
CN112469413B (zh) 2018-05-25 2024-01-12 伊马拉公司 6-[(3s,4s)-4-甲基-1-(嘧啶-2-基甲基)吡咯烷-3-基]-3-四氢吡喃-4-基-7h-咪唑并[1,5-a]吡嗪-8-酮的一水合物和结晶形态
EP3843737A4 (en) 2018-08-31 2022-06-01 Imara Inc. PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
CN109847063B (zh) * 2018-12-26 2023-02-28 南方医科大学皮肤病医院（广东省皮肤病医院、广东省皮肤性病防治中心、中国麻风防治研究中心） Rsk信号通路抑制剂在抑制沙眼衣原体感染中的应用
CN109438403A (zh) * 2018-12-28 2019-03-08 凯瑞斯德生化(苏州)有限公司 一种5-氨基苯并呋喃-2-甲酸乙酯的制备方法
EP3924352A4 (en) * 2019-02-11 2022-11-16 Phoenix Molecular Designs CRYSTALLINE FORMS OF AN RSK INHIBITOR
WO2022251597A1 (en) * 2021-05-28 2022-12-01 Verge Analytics, Inc. Methods of treating neurological disorders with modulators of ribosomal protein s6 kinase alpha-1 (rsk1) and ribosomal protein s6 kinase alpha-3 (rsk2)
AU2022380979A1 (en) 2021-11-02 2024-06-06 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
CN119451961A (zh) * 2022-06-07 2025-02-14 广州科恩泰生物医药科技有限公司 一种具有rsk抑制作用的羧酰胺衍生物、包含其的药物组合物及其用途
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
CA2268164A1 (en) 1996-10-08 1998-04-16 Yao-Chang Xu New serotonin 5-ht1f agonists
ZA979961B (en) * 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
JP2001524124A (ja) 1997-05-07 2001-11-27 ガレン（ケミカルズ）リミティド テストステロンおよびテストステロン前駆体の投与のための膣内薬物送達用具
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
EP1495016A2 (en) * 2002-04-09 2005-01-12 Astex Technology Limited Heterocyclic compounds and their use as modulators of p38 map kinase
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2006002421A2 (en) * 2004-06-24 2006-01-05 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7790712B2 (en) 2005-03-17 2010-09-07 Boehringer Ingelheim Pharmaceutical, Inc. Substituted [1,4]diazepino[1,2-A]indoles and azepino[1,2-A]indoles as anti-cytokine inhibitors
FR2884516B1 (fr) 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
EP2155675B1 (en) * 2007-06-12 2014-02-19 Provid Pharmaceuticals, Inc. Kinase inhibitors, compositions thereof, and methods of use therewith
ES2614498T3 (es) * 2007-09-14 2017-05-31 The Regents Of The University Of Michigan Inhibidores de ATPasa F1F0 y métodos relacionados
GB0718870D0 (en) 2007-09-27 2007-11-07 Univ Dundee Modulation of RSK
JP5643332B2 (ja) 2009-12-07 2014-12-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピロロピリジンまたはベンゾイミダゾールコアを含有する複素環化合物
US9150577B2 (en) 2009-12-07 2015-10-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds containing an indole core
CA2913583C (en) 2012-06-04 2019-08-06 Phoenix Molecular Diagnostics Ltd. Methods of inhibiting rsk for treatment of breast cancer
EP2943485B1 (en) * 2013-01-14 2017-09-20 Incyte Holdings Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
CN103724251B (zh) * 2014-01-18 2015-07-22 福州大学 一种靶向stat3的小分子化合物及其制备方法和应用
WO2015155042A1 (en) 2014-04-07 2015-10-15 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
ES2858753T3 (es) 2016-02-19 2021-09-30 Phoenix Molecular Designs Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer

Also Published As

Publication number Publication date
BR112018016968A2 (pt) 2019-01-08
US20190134029A1 (en) 2019-05-09
EP3416964B1 (en) 2020-12-16
CN109071542A (zh) 2018-12-21
US20210186961A1 (en) 2021-06-24
MX2018010028A (es) 2019-01-21
US10758530B2 (en) 2020-09-01
JP2019505541A (ja) 2019-02-28
CN109071542B (zh) 2021-07-20
US20170240549A1 (en) 2017-08-24
US20170327501A1 (en) 2017-11-16
JP7289876B2 (ja) 2023-06-12
KR102746242B1 (ko) 2024-12-23
IL261170A (en) 2018-10-31
AU2017220738B2 (en) 2022-02-24
EP3416964A4 (en) 2019-09-18
DK3416964T3 (da) 2021-02-22
ES2858753T3 (es) 2021-09-30
WO2017141116A8 (en) 2017-11-09
KR20180129783A (ko) 2018-12-05
CA3014395A1 (en) 2017-08-24
CN113620950A (zh) 2021-11-09
US10081632B2 (en) 2018-09-25
PL3416964T3 (pl) 2021-10-18
MX376974B (es) 2025-03-07
EP3848373A1 (en) 2021-07-14
US9771366B2 (en) 2017-09-26
JP6912486B2 (ja) 2021-08-04
AU2017220738A1 (en) 2018-08-30
JP2021176857A (ja) 2021-11-11
IL261170B (en) 2021-12-01
EP3416964A1 (en) 2018-12-26
WO2017141116A1 (en) 2017-08-24
CO2018008846A2 (es) 2018-11-13

Similar Documents

Publication Publication Date Title
IL261170B (en) Carboxamide history used as rsk inhibitors
ME03740B (me) Jedinjenja indol karboksamida korisna kao inhibitori kinaze
IL256808A (en) Heteroaryl derivatives as parp inhibitors
IL256556B (en) Oxopyridine histories are transmuted
ZA201800563B (en) Polycyclic amide derivatives as cdk9 inhibitors
SG11201706729SA (en) Derivatives of sobetirome
HUE056357T2 (hu) Szobetirom származékok
ZA201607658B (en) Carboxamide derivatives
AP2016009554A0 (en) Carboxamide derivatives
SG11201701378WA (en) Pyrido-oxazinone derivatives as tnap inhibitors
EP3112343A4 (en) Amide derivatives
IL266121A (en) A history of metamorphosed quinoxaline as an inhibitor of pfkfb
IL248801A0 (en) Carboxamide history
HK1229326A1 (en) Carboxamide derivatives